

ANNOUNCEMENT FROM FRISQ'S EXTRA GENERAL MEETING

The extra general meeting ("EGM") of Frisq Holding AB (publ) ("FRISQ" or the "Company") was held today on 31 October 2022 and the following resolutions were passed by the meeting.

Resolution on approval of the sale of all shares in the subsidiary

The EGM resolved, in accordance with the board of directors' proposal, to approve the sale of all shares in Frisq AB, reg.no 556783-5664, conditional on the share purchase agreement being entered into no later than 1 December 2022 with Cambio Healthcare System AB and that the purchase price amounts to at least an amount of SEK 40 million divided into a purchase price of SEK 31 million upon closing and an additional purchase price of SEK 9 million within a 6-month period. The share transfer agreement must in other matters be entered into on market terms.

The date of transfer of the shares is expected to be December 1, 2022, but can be postponed for another month thereafter if necessary.

The Company will announce additional information in the event that a share purchase agreement has been entered into or if the conditions for approval by the general meeting can no longer be fulfilled.

Authorization for the board to issue shares, convertibles and/or warrants

The EGM resolved, in accordance with the board of directors' proposal, to authorize the board, on one or more occasions, with or without preferential rights for shareholders, to issue in total a maximum of shares, warrants and/or convertible, corresponding to not more than 40 percent of the share capital of the Company after completed issuances based on the number of shares at the time of the extra general meeting, to be paid in cash, by set-off or in-kind.

The reason for the authorization and deviation from the shareholders' preferential rights is to enable raising capital for expansion through acquisitions of companies or assets and for the business of the Company as well as to adapt the Company's capital and/or ownership structure. If issuances are carried out with deviation from the shareholders' preferential rights, such issue shall be made in accordance with customary market terms. If the board of directors finds it suitable in order to enable delivery of shares in connection with a share issuance as set out above it may be made at a subscription price corresponding to the shares quota value.

For further details regarding the resolutions set out above refer to the notice and complete proposals available at the Company's website, www.frisqholding.se.

For further information:

Mats Lindstrand, CEO FRISQ Holding AB
E-mail: investor@frisq.se

About FRISQ:

FRISQ is a healthtech company built on the conviction that the quality of the care you get should not be dependent on your ability to navigate a complex system and constantly evolving treatments. The software solution [FRISQ Care](#) enables the creation of personalized, digital care plans that facilitate collaboration and secure information sharing between care teams, doctors and patients through the same platform.

Since 2016, FRISQ has been listed on Nasdaq First North Stockholm under the symbol "FRISQ". FNCA Sweden AB is FRISQ's Certified Adviser and can be reached via the following contact information: +46 8 528 00 399, info@fnca.se

The publication is a translation of the original Swedish text. In the event of inconsistency or discrepancy between the Swedish version and this publication, the Swedish language version shall prevail.

For more information, please visit: www.frisqholding.se

This information is information that FRISQ Holding is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-10-31 12:50 CET.

Attachments

[Announcement from FRISQ's extra general meeting](#)